Lineage Cell Therapeutics Past Earnings Performance
Past criteria checks 0/6
Lineage Cell Therapeutics's earnings have been declining at an average annual rate of -14.7%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 15.5% per year.
Key information
-14.71%
Earnings growth rate
-5.18%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 15.47% |
| Return on equity | -121.48% |
| Net Margin | -434.44% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
LCTX: AlloSCOPE Pipeline And Ophthalmology Data Will Support Future Upside Potential
Analysts have lifted their price target on Lineage Cell Therapeutics by $0.36 to $5.50, citing updated assumptions around potential revenue growth, profit margins, and a lower future P/E multiple following recent bullish coverage and a $1 target increase from B. Riley.
Cell Therapy Manufacturing And Partner Dependence Will Pressure Margins Yet Leave Long Runway
Catalysts About Lineage Cell Therapeutics Lineage Cell Therapeutics develops allogeneic cell therapies using its AlloSCOPE manufacturing platform for conditions linked to loss of specific cell function. What are the underlying business or industry changes driving this perspective?LCTX: AlloSCOPE Platform Progress Will Support Future Pipeline Monetization Potential
Analysts have raised their price target on Lineage Cell Therapeutics by $1, citing updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that reflect recent bullish coverage and target revisions from the Street. Analyst Commentary Bullish Takeaways Bullish analysts point to recent target revisions as support for a higher fair value, suggesting that prior assumptions for revenue growth, profit margins, and future P/E were conservative.Aging Trends And Regenerative Medicine Will Open New Avenues
Lineage Cell Therapeutics' higher net profit margin and a slight increase in its discount rate have contributed to a raised consensus analyst price target, now at $4.17. What's in the News First-ever chronic spinal cord injury patient treated in Lineage's DOSED clinical study, which evaluates a novel device for delivering OPC1 cells directly to injury sites; OPC1 has received RMAT and Orphan Drug designations from the FDA.Advancements In OpRegen And Genentech Collaborations Will Unlock Potential
Strong data support and partnership expansions, especially for OpRegen, could significantly enhance future revenue and market share in dry AMD.Revenue & Expenses Breakdown
How Lineage Cell Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 15 | -64 | 19 | 0 |
| 31 Dec 25 | 15 | -64 | 18 | 0 |
| 30 Sep 25 | 11 | -68 | 18 | 0 |
| 30 Jun 25 | 11 | -41 | 18 | 0 |
| 31 Mar 25 | 10 | -16 | 18 | 0 |
| 31 Dec 24 | 9 | -19 | 18 | 0 |
| 30 Sep 24 | 9 | -20 | 15 | 0 |
| 30 Jun 24 | 6 | -24 | 14 | 0 |
| 31 Mar 24 | 8 | -24 | 14 | 0 |
| 31 Dec 23 | 9 | -21 | 14 | 0 |
| 30 Sep 23 | 9 | -23 | 17 | 4 |
| 30 Jun 23 | 11 | -22 | 18 | 8 |
| 31 Mar 23 | 12 | -24 | 19 | 11 |
| 31 Dec 22 | 15 | -26 | 23 | 14 |
| 30 Sep 22 | 14 | -49 | 23 | 35 |
| 30 Jun 22 | 13 | -51 | 23 | 34 |
| 31 Mar 22 | 9 | -49 | 23 | 34 |
| 31 Dec 21 | 4 | -43 | 18 | 34 |
| 30 Sep 21 | 4 | -12 | 17 | 12 |
| 30 Jun 21 | 2 | -12 | 16 | 12 |
| 31 Mar 21 | 2 | -14 | 15 | 12 |
| 31 Dec 20 | 2 | -21 | 16 | 12 |
| 30 Sep 20 | 3 | -27 | 16 | 13 |
| 30 Jun 20 | 3 | -36 | 17 | 14 |
| 31 Mar 20 | 3 | -59 | 18 | 16 |
| 31 Dec 19 | 4 | -12 | 19 | 18 |
| 30 Sep 19 | 3 | -52 | 22 | 18 |
| 30 Jun 19 | 3 | 31 | 24 | 19 |
| 31 Mar 19 | 5 | 57 | 24 | 20 |
| 31 Dec 18 | 5 | -46 | 25 | 21 |
| 30 Sep 18 | 5 | -73 | 23 | 22 |
| 30 Jun 18 | 6 | -125 | 22 | 24 |
| 31 Mar 18 | 4 | -133 | 21 | 23 |
| 31 Dec 17 | 3 | -20 | 20 | 24 |
| 30 Sep 17 | 4 | 47 | 19 | 26 |
| 30 Jun 17 | 3 | 64 | 19 | 26 |
| 31 Mar 17 | 4 | 100 | 22 | 29 |
| 31 Dec 16 | 6 | 34 | 28 | 36 |
| 30 Sep 16 | 6 | 25 | 33 | 42 |
| 30 Jun 16 | 7 | -20 | 36 | 47 |
| 31 Mar 16 | 8 | -54 | 36 | 47 |
| 31 Dec 15 | 7 | -47 | 29 | 43 |
| 30 Sep 15 | 7 | -45 | 24 | 41 |
| 30 Jun 15 | 6 | -39 | 20 | 38 |
Quality Earnings: LCTX is currently unprofitable.
Growing Profit Margin: LCTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LCTX is unprofitable, and losses have increased over the past 5 years at a rate of 14.7% per year.
Accelerating Growth: Unable to compare LCTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LCTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: LCTX has a negative Return on Equity (-121.48%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/03 11:03 |
| End of Day Share Price | 2026/06/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lineage Cell Therapeutics, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| John Newman | Canaccord Genuity |